The purpose of this study is to see if an experimental drug, called milvexian is safe, effective and useful in reducing risk of developing blood clots, stroke, or another heart attack among subjects with a recent heart attack or angina (chest pain) episode. An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA).
Contact phone
517-364-5760
Contact email
scri@sparrow.org
Principal investigator
Dr. Mohammed Qintar, MD
Trial Category
Heart & Vascular
Trial SubCategory
Atrial Fibrillation
Webform